BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan · Delayed Price · Currency is JPY 50.00
-1.00 (-1.96%)
Aug 6, 2026, 3:04 PM JST
TYO:4594 Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Cash & Equivalents | 2,156 | 810.47 | 1,057 | 6,528 | 4,950 |
Cash & Short-Term Investments | 2,156 | 810.47 | 1,057 | 6,528 | 4,950 |
Cash Growth | 166.04% | -23.35% | -83.80% | 31.88% | - |
Accounts Receivable | 0.06 | 1.15 | 0.01 | 77 | 54 |
Other Receivables | 50.8 | 63.53 | 37.98 | - | - |
Receivables | 50.85 | 64.68 | 37.99 | 77 | 54 |
Inventory | - | - | - | 27 | 42 |
Other Current Assets | 347.18 | 196.17 | 85.62 | 268 | 193 |
Total Current Assets | 2,554 | 1,071 | 1,181 | 6,900 | 5,239 |
Property, Plant & Equipment | - | - | - | 266 | 115 |
Long-Term Investments | - | - | - | 55 | 39 |
Other Intangible Assets | - | - | - | 13 | 13 |
Other Long-Term Assets | 50.63 | 49.3 | 49.3 | 1 | 2 |
Total Assets | 2,605 | 1,121 | 1,230 | 7,235 | 5,408 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Accounts Payable | 0.03 | 0.04 | 0.02 | 8 | 22 |
Accrued Expenses | 3.18 | 3.28 | 6.09 | - | - |
Short-Term Debt | - | 25 | 112.5 | - | - |
Current Income Taxes Payable | 29.14 | 17.07 | 12.82 | 198 | 113 |
Other Current Liabilities | 129 | 86.28 | 59.59 | 23 | 26 |
Total Current Liabilities | 161.36 | 131.66 | 191.01 | 229 | 161 |
Pension & Post-Retirement Benefits | 48.47 | 41.22 | 37.61 | 31 | 25 |
Long-Term Deferred Tax Liabilities | - | - | - | 4 | 4 |
Other Long-Term Liabilities | 26.59 | 22.74 | 22.65 | 21 | 18 |
Total Liabilities | 236.41 | 195.63 | 251.27 | 285 | 208 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Common Stock | 2,575 | 1,200 | 650.66 | 5,419 | 3,774 |
Additional Paid-In Capital | 4,883 | 3,508 | 2,959 | 5,403 | 3,757 |
Retained Earnings | -5,110 | -3,805 | -2,654 | -3,929 | -2,352 |
Treasury Stock | -0 | -0 | - | - | - |
Comprehensive Income & Other | 20.27 | 21.58 | 22.85 | 57 | 20 |
Total Common Equity | 2,368 | 924.99 | 978.99 | 6,950 | 5,199 |
Minority Interest | - | - | - | - | 1 |
Shareholders' Equity | 2,368 | 924.99 | 978.99 | 6,950 | 5,200 |
Total Liabilities & Equity | 2,605 | 1,121 | 1,230 | 7,235 | 5,408 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
Total Debt | - | 25 | 112.5 | - | - |
Net Cash (Debt) | 2,156 | 785.47 | 944.86 | 6,528 | 4,950 |
Net Cash Growth | 174.51% | -16.87% | -85.53% | 31.88% | - |
Net Cash Per Share | 19.33 | 9.64 | 14.73 | 170.73 | 145.52 |
Filing Date Shares Outstanding | 138.89 | 90.49 | 64.16 | 41.86 | 37.22 |
Total Common Shares Outstanding | 138.89 | 90.49 | 64.16 | 41.84 | 37.22 |
Working Capital | 2,393 | 939.65 | 989.95 | 6,671 | 5,078 |
Book Value Per Share | 17.05 | 10.22 | 15.26 | 166.13 | 139.69 |
Tangible Book Value | 2,368 | 924.99 | 978.99 | 6,937 | 5,186 |
Tangible Book Value Per Share | 17.05 | 10.22 | 15.26 | 165.82 | 139.34 |